Highest-materiality recent filing
ProAssurance acquired by The Doctors Company for $25.00 per share in all-cash merger
Merger closed June 26, 2026; each PRA share converted to $25.00 cash.
ProAssurance gets all regulatory approvals for merger with The Doctors Company; closing June 26
All insurance regulatory approvals received as of June 23, 2026.
Final insurance regulatory approvals received from Alabama, DC, Illinois, Missouri, Pennsylvania, Texas, Vermont, plus Lloyd's of London and Cayman Islands.
ProAssurance Q1 operating income $12.7M; merger with Doctors Company targets June 30 close
Net income $8.5M ($0.16 diluted EPS); operating income $12.7M ($0.25 diluted EPS).
ProAssurance reports Q4 net income $33.4M ($0.64 EPS); merger update
Q4 net income $33.4M ($0.64 diluted EPS); operating income $42.4M ($0.82 diluted EPS).
ProAssurance approves early bonus payouts to NEOs to mitigate Section 280G impact
Compensation Committee approved early payments of ~80% of 2025 annual cash incentive awards to NEOs.
ProAssurance Q3 net income $1.4M; merger with Doctors Co. pending regulatory approvals
Q3 net income $1.4M ($0.03 diluted EPS); operating income $7.9M ($0.15 diluted EPS).
ProAssurance reports Q2 net income $21.9M ($0.42 EPS); merger with Doctors Co. on track
Net income $21.9M ($0.42 diluted EPS); operating income $26.8M ($0.52 diluted EPS) for Q2 2025.
FTC grants early termination of HSR waiting period for ProAssurance acquisition by Doctors Company
U.S. FTC granted early termination of HSR Act waiting period on July 2, 2025.
ProAssurance shareholders approve acquisition by The Doctors Company with over 99% vote in favor
Stockholders voted 38,225,337 for, 363,050 against, 22,192 abstain; over 99% of votes cast in favor.
ProAssurance elects three directors, board reduced to nine; audit chair changed
Stockholders elected DiPiazza, Frei, and Syphax to three-year terms at May 21, 2025 annual meeting.
Net loss of $5.8M ($0.11 diluted loss); operating income of $6.8M ($0.13 diluted share).
ProAssurance to be acquired by The Doctors Company for $25.00 per share in cash
Merger consideration of $25.00 cash per share; value to be paid to stockholders (excluding certain shares).
ProAssurance to be acquired by The Doctors Company for $25/share cash, ~$1.3B
Stockholders receive $25.00 per share in cash, a ~60% premium to March 18 close.
ProAssurance Q4 net income $16.2M ($0.31/diluted); full-year $52.7M ($1.03/diluted)
Q4 2024 net income $16.2M ($0.31/diluted); operating income $18.3M ($0.36/diluted).
ProAssurance Q3 net income $16.4M; operating income $0.34/sh, combined ratio 99.5%
Net income of $16.4M ($0.32 diluted EPS); operating income $17.3M ($0.34 diluted EPS).
ProAssurance reports Q2 2024 net income $15.5M, EPS $0.30; operating income $11.5M
Net income $15.5M ($0.30 diluted EPS); operating income $11.5M ($0.23 diluted EPS).
ProAssurance Q1 operating EPS $0.08; board reduces to 10 with new directors
Operating EPS of $0.08 vs loss of $0.14 in Q1 2023; net income $4.6M.
ProAssurance elects Bielen and Pierce to board; four incumbents depart, board size to 10
Richard J. Bielen and Staci M. Pierce elected as new directors; four incumbents (Gorrie, Haydar, Spinosa, Wilson) did not stand for re-election.
ProAssurance Q1 net income $4.6M ($0.09 EPS); operating income $4.2M
Net income $4.6M ($0.09 diluted EPS); operating income $4.2M ($0.08 diluted EPS).
Stockholders re-elected Samuel A. Di Piazza Jr., Fabiola Cobarrubias, Edward L. Rand Jr., and Katisha T. Vance to three-year board terms.
ProAssurance corrects 10-K equity compensation table; zero shares remain available
Typo in Form 10-K's equity compensation table: number of securities available for future issuance was incorrectly reported.
ProAssurance posts FY23 net loss of $38.6M; workers' comp combined ratio 121.5%
FY23 non-GAAP operating loss $7.3M ($0.14/diluted share); Q4 operating loss $2.5M ($0.05/share).
ProAssurance reports Q4 net income of $6.4M but operating loss; new business jumps 103%
Net income of $6.4M ($0.12 diluted EPS); operating loss of $2.5M (-$0.05 diluted EPS).
ProAssurance Q3 net loss $49.4M, $44M goodwill impairment, refinances $250M notes
Net loss of $49.4M in Q3 2023 vs. $9.1M loss in Q3 2022; non-GAAP operating loss of $3.7M.
ProAssurance reports Q3 net loss of $49.4M ($0.95/share); operating loss $3.7M
Net loss of $49.4M ($0.95 diluted EPS); operating loss of $3.7M ($0.07).
Dr. Ross E. Taubman, PICA Group President, to retire effective March 31, 2024, after 12 years of service.
ProAssurance Q2 net income $10.6M vs -$1.7M YoY; operating EPS $0.16 vs $0.30
Q2 2023 net premiums earned $247.9M (flat YoY); total revenues $291.8M vs $255.8M.
ProAssurance Q2 net income $10.6M ($0.20 EPS); investment income up 44%
Operating income of $8.6M ($0.16 EPS) vs net income $10.6M ($0.20 diluted EPS).
ProAssurance files proposed settlement in shareholder lawsuit; insurer to fund payment
Unopposed motion filed June 22, 2023 to settle Sheet Metal Workers Local 19 Pension Fund class action.
ProAssurance reports Q1 2023 net loss of $6.2M, combined ratio of 114.3% in investor presentation
Q1 2023 net loss of $6.2M; non-GAAP operating loss of $8.1M ($0.15 diluted).
ProAssurance posts Q1 2023 net loss of $6.2M; diluted EPS -$0.11
Net loss of $6.2M ($0.11 diluted loss); operating loss of $8.1M ($0.15 diluted loss).
ProAssurance suspends quarterly cash dividend; will use share repurchases instead
Board suspended quarterly cash dividend, citing current share trading price.
ProAssurance amends revolver to $250M, adds $125M term loan to refinance Nov 2023 senior notes
Revolver extended to April 2028, capacity $250M plus $50M accordion feature.
ProAssurance declares $0.05 quarterly dividend, payable April 13, 2023
Cash dividend of $0.05 per common share declared on March 8, 2023.
ProAssurance reports near-breakeven FY2022 net loss; Specialty P&C combined ratio 104.2%
FY2022 net loss of $0.4M; non-GAAP operating income $24.5M ($0.45 diluted EPS).
ProAssurance announces Mike Boguski retirement as President of Specialty P&C effective June 30, 2023
Mike Boguski to retire as President of Specialty Property & Casualty on June 30, 2023.
ProAssurance Q4 net income $13.9M ($0.26 EPS); full year gross premiums $1.1B (+15%)
Net income $13.9M ($0.26 diluted EPS); operating income $3.5M ($0.06 diluted EPS) for Q4 2022.
ProAssurance declares $0.05 quarterly dividend, sets May 24, 2023 annual meeting
Dividend of $0.05 per share payable January 10, 2023 to holders of record December 22, 2022.
ProAssurance Q3 net loss of $9.1M vs year-ago profit; revenue down 12%
Q3 2022 net loss of $9.1M ($0.17 per share) vs net income of $12.2M in Q3 2021.
ProAssurance reports Q3 net loss of $9.1M; operating loss $0.06 per share
Net loss of $9.1M ($0.17 diluted EPS); operating loss of $3.0M ($0.06 per share).
Q2 2022 net loss $1.7M versus net income $92.1M in Q2 2021; non-GAAP operating income fell to $16.3M from $26.6M.
ProAssurance declares $0.05 quarterly dividend, payable Oct 13, 2022
Dividend of $0.05 per common share declared by Board on Sept 7, 2022.
ProAssurance Q2 net loss $0.03/share; operating EPS $0.30; gross premiums up 13%
Net loss $1.7M ($0.03 diluted); operating income $16.3M ($0.30 diluted).
ProAssurance reelects four directors, declares $0.05 quarterly dividend
Shareholders re-elected Kedrick Adkins Jr., Bruce Angiolillo, Maye Head Frei, and Scott Syphax to the board for three-year terms; each received over 96% of votes cast.
ProAssurance Q1 net loss $3.6M; non-GAAP operating EPS $0.14 improves from $0.04
Gross premiums written rose 49% YoY to $335.6M, driven by NORCAL acquisition.
ProAssurance reports Q1 net loss $3.6M, operating income $7.7M
Net loss of $3.6M ($0.07 diluted EPS) for three months ended March 31, 2022.
ProAssurance Executive Chairman Stan Starnes to retire May 24, 2022
W. Stancil Starnes will retire at the end of his term and not stand for re-election at the May 24, 2022 annual meeting.
ProAssurance declares $0.05 quarterly dividend, payable April 7, 2022
Dividend of $0.05 per common share declared, payable April 7, 2022 to holders of record March 24, 2022.
ProAssurance reports FY2021 gross premiums $960M, NORCAL acquisition closed, renewal rates up 8%
NORCAL acquisition added ~$300M GPW and ~$1.6B investments; ProAssurance now #3 HCPL insurer in U.S.
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
Richard Anderson (Chairman and Chief Executive Officer); Robert E. White, Jr. (President); Marco Vanderlaan (Chief Financial Officer and Treasurer); and David A. McHale (Secretary).
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
Kedrick D. Adkins, C.P.A., who had served on the Board for seven years, did not stand for re-election
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
our stockholders elected Samuel A. DiPiazza, Jr., C.P.A., Maye Head Frei, and Scott C. Syphax to our Board of Directors
M. James Gorrie, Ziad R. Haydar, M.D., Frank A. Spinosa, D.P.M., and Thomas A. S. Wilson, Jr., M.D., each of whom had served at least nine years on the board, did not stand for re-election
M. James Gorrie, Ziad R. Haydar, M.D., Frank A. Spinosa, D.P.M., and Thomas A. S. Wilson, Jr., M.D., each of whom had served at least nine years on the board, did not stand for re-election
Staci M. Pierce, J.D. (new member of the board)
M. James Gorrie, Ziad R. Haydar, M.D., Frank A. Spinosa, D.P.M., and Thomas A. S. Wilson, Jr., M.D., each of whom had served at least nine years on the board, did not stand for re-election
Max materiality 1.00 · Median 0.65 · Most common event earnings